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CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS
Follicular Lymphoma International Prognostic Index
Philippe Solal-Ce´ligny, Pascal Roy, Philippe Colombat, Josephine White, Jim O. Armitage, Reyes Arranz-Saez, Wing Y. Au, Monica Bellei,
Pauline Brice, Dolores Caballero, Bertrand Coiffier, Eulogio Conde-Garcia, Chantal Doyen, Massimo Federico, Richard I. Fisher,
Javier F. Garcia-Conde, Cesare Guglielmi, Anton Hagenbeek, Corinne Haı¨oun, Michael LeBlanc, Andrew T. Lister,
Armando Lopez-Guillermo, Peter McLaughlin, Noe¨l Milpied, Pierre Morel, Nicolas Mounier, Stephen J. Proctor, Ama Rohatiner,
Paul Smith, Pierre Soubeyran, Herve´ Tilly, Umberto Vitolo, Pier-Luigi Zinzani, Emanuele Zucca, and Emili Montserrat
The prognosis of follicular lymphomas
(FL) is heterogeneous and numerous
treatments may be proposed. A validated
prognostic index (PI) would help in evalu-
ating and choosing these treatments.
Characteristics at diagnosis were col-
lected from 4167 patients with FL diag-
nosed between 1985 and 1992. Univariate
and multivariate analyses were used to
propose a PI. This index was then tested
on 919 patients. Five adverse prognostic
factors were selected: age (> 60 years vs
< 60 years), Ann Arbor stage (III-IV vs I-II),
hemoglobin level (< 120 g/L vs > 120
g/L), number of nodal areas (> 4 vs < 4),
and serum LDH level (above normal vs
normal or below). Three risk groups were
defined: low risk (0-1 adverse factor, 36%
of patients), intermediate risk (2 factors,
37% of patients, hazard ratio [HR] of 2.3),
and poor risk (> 3 adverse factors, 27%
of patients, HR  4.3). This Follicular Lym-
phoma International Prognostic Index
(FLIPI) appeared more discriminant than
the International Prognostic Index pro-
posed for aggressive non-Hodgkin lym-
phomas. Results were very similar in the
confirmation group. The FLIPI may be
used for improving treatment choices,
comparing clinical trials, and designing
studies to evaluate new treatments.
(Blood. 2004;104:1258-1265)
© 2004 by The American Society of Hematology
Introduction
Follicular lymphomas (FLs) account for one third of non-
Hodgkin lymphomas (NHLs) in adults. The course of the
disease is usually characterized by a response to initial treat-
ment, followed by relapses, sometimes associated with histo-
logic transformation into high-grade NHL.1 From “watchful
waiting” to high-dose therapy, numerous treatment options have
been proposed for patients with FL. Meanwhile, there is no
consensus on any of these approaches. Agreement in the
treatment algorithm of patients with FL would be made easier by
a simple, validated, and accurate prognostic index similar to the
International Prognostic Index proposed for aggressive NHLs in
1993.2 In retrospective analyses of a series of FL or indolent
NHLs, several characteristics were associated with a poor
clinical outcome such as advanced age,3-10 male sex,4,7,11,12
disseminated disease according to Ann Arbor classification,1,4
high number of nodal3,7 and/or extra nodal involvement sites,12
presence of bulky tumor(s),6,8 increased serum lactate dehydroge-
nase (LDH)13 and/or 2 microglobulin14 levels, poor performance
status,5,6 and a low hemoglobin level.4 From these analyses, a few
prognostic indices have been proposed3,4,9,12 but none of them has
been validated and/or widely used. Several retrospective analyses
have also suggested that the International Prognostic Index (IPI)
initially designed for aggressive NHLs could also be used in
indolent NHLs.15-20 However, some important prognostic factors
may have been missed since the IPI was not designed to
investigate prognostic factors in FL. Moreover, when using the
IPI, very few patients (around 10%-15%) with FL are classified
in the poor-risk category. Because of this, the IPI is not
appropriate to identify patients in whom intensive therapy has to
be tested. An international cooperative study was thus designed
to collect the data on initial characteristics of a large number of
patients with FL and to propose a prognostic index for FL. This
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cooperative study culminated in a proposal for a Follicular
Lymphoma International Prognostic Index (FLIPI).
Patients and methods
Patients
The following inclusion criteria were used: (1) Follicular lymphoma
according to the Working Formulation for Clinical Usage21 and/or the Kiel
classification,22 which were in use at the time of the period of inclusion. All
cell types (small-cell, mixed, or large-cell FL) could be included in the
study. No central pathology review was performed. (2) Initial diagnosis
between January 1, 1985, and December 31, 1992. (3) Staging procedures
including at least a CT scan of the thorax, abdomen and pelvis, or
lymphangiography plus abdominal and pelvis echography, bone marrow
biopsy, routine blood counts, and biochemistry tests. (4) Follow-up until
death, or for at least 5 years for surviving patients. The FLIPI was a
retrospective study that relied on patients included in several trials
conducted according to legal guidelines in each country at the time of study.
Consent for this study was part of the informed consent given for these
trials. The study was approved by the French Committee for the Use of
Computerized Medical Data.
Data collection
Demographic characteristics and initial staging. Nodal areas considered
were cervical, axillary, inguino-crural, para aortic and/or iliac, celiac and/or
mesenteric, and other ancillary nodal sites. Involved area (or areas) either
clinically or on CT scan (or scans) was quoted as 1 (2 if bilateral) and each
patient had between 0 and 8 or more involved areas (Figure 1). All extra
nodal areas were taken into account. In the absence of any agreement on a
threshold, it was not possible to define a bulky tumor. As in the International
Prognostic Index for aggressive NHLs2 the spleen was considered as an
extra nodal site.
Clinical and biologic characteristics. The following clinical and
biologic characteristics were related to disease extension and/or tumor bulk:
cell type, Ann Arbor stage, serum LDH, and 2 microglobulin levels
(expressed as the ratio of the measured value to the upper limit of normal
for the center). The following clinical and biologic characteristics were
related to the effects of FL on the host: performance status according to the
Eastern Cooperative Oncology Group scale, presence or absence of any B
symptoms, anemia, lymphocytopenia, decreased serum albumin level,
increased erythrocyte sedimentation rate (ESR), thrombocytopenia.
Statistical analysis
Overall survival was the end point of all statistical analyses. Survival rates
and corresponding standard errors were estimated using Kaplan and Meier
Figure 1. Mannikin used for counting the number of involved areas. See
“Demographic characteristics and initial staging” in the text. Each rectangle corre-
sponds to a nodal area. Figure 2. Overall survival of the study population (n 4167).
Table 1. Accrual of patients in the FLIPI study
Group (G) or
center (C)
Country or
countries
No. of
patients
Barcelona G Spain 142
Becquerel H Hospital C France 127
Bellinzona C Switzerland 60
Bergamo Hospital C Italy 42
Bergonie´ Institute C France 65
BNLI G United Kingdom 474
Bretonneau Hospital C France 35
EORTC G Europe 347
GELF G France, Belgium 567
GOELAMS G France 118
Hotel Dieu Nantes Hospital C France 42
Huriez L Hospital C France 87
Intergruppo Italiano Linfomi G Italy 848
LNH-Pro G Spain 55
Lyon-Sud C France 197
MD Anderson C United States 451
Mondor H Hospital C France 34
Mont-Godinne Hospital C Belgium 27
Nebraska Lymphoma Study Group C United States 186
Queen Mary Hospital Hong Kong C China 66
Saint Bartholomew Hospital C United Kingdom 108
Saint Louis Hospital C France 33
Salamanca Hospital C Spain 18
Santander Hospital C Spain 57
Sapienza (La) Roma C Italy 94
SNLG G United Kingdom 557
SWOG G United States 283
Data are organized alphabetically by center. BNLI indicates British National
Lymphoma Intergroup; EORTC, European Organization for the Treatment of Cancer;
GELF, Groupe d’Etude des Lymphomes Folliculaires; GOELAMS, Groupe Ouest-Est
des Leuce´mies Aigue¨s et Autres Maladies du Sang; SNLG, Scotland and Newcastle
Lymphoma Study Group; and SWOG, SouthWest Oncology Group.
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estimators.23 Survival curves were compared applying the log-rank test.
Continuous biologic variables were dichotomized applying usual clinical
thresholds. These a priori chosen thresholds were checked using cubic
smoothing spline24 and the risk function of a proportional hazard model.25 A
prognostic model was built fitting a proportional hazard model with all
variables that significantly influenced the overall survival at a level of P
values less than or equal to .05 in the univariate analysis (full model). A
forward stepwise Cox regression analysis25 was then performed, including
age and sex and, successively, extent of the disease, influence of the disease
on the host, and other biologic variables. The prognostic index was derived
from the prognostic model resulting from the Cox analysis. The clinical
committee of the project asked for an index that would include no more than
5 variables in order to make its use easier in routine practice. If the Cox
analysis retained more than 5 variables, it was decided to select the 5
variables from the prognostic model that produced the smallest loss of
discriminating power. For choosing the most accurate model, all the
Table 2. Characteristics of the patients and results of the univariate analysis of prognostic factors
Parameter n %
5-year survival,
% (SE)
10-year survival,
% (SE)
Log rank,
P
Sex 4167 .0025
Female 49 72.5 (1.0) 51.0 (1.4)
Male 51 68.7 (1.0) 46.2 (1.4)
Age 4167  104
Younger than 60 y 63 78.1 (0.8) 58.4 (1.2)
60 y or older 37 57.7 (1.3) 32.3 (1.6)
Cell type 3511 .1065
Small cell 50 71.8 (1.1) 48.6 (1.5)
Mixed 41 71.1 (1.2) 50.4 (1.7)
Large cell 9 66.1 (2.7) 40.0 (3.9)
Ann Arbor stage 4162  104
I-II 22 83.2 (1.2) 64.3 (2.0)
III-IV 78 67.0 (0.8) 44.1 (1.1)
B symptoms 3965  104
Absence 81 73.8 (0.8) 50.7 (1.2)
Presence 19 55.8 (1.8) 36.8 (2.3)
Performance status (ECOG) 3602  104
0-1 88 72.4 (0.8) 50.0 (1.2)
More than 1 12 58.6 (2.4) 37.8 (3.0)
Number of nodal sites 3322  104
0-4 65 77.0 (0.9) 54.6 (1.4)
5 or more 35 63.7 (1.4) 42.1 (1.9)
Number of extra nodal sites other than bone marrow 3741  104
0 62 76.1 (0.9) 55.4 (1.3)
1 or more 38 63.7 (1.3) 40.8 (1.7)
Bone marrow involvement 4016  104
Absence 52 75.6 (0.9) 56.2 (1.3)
Presence 48 65.7 (1.1) 40.4 (1.6)
Spleen involvement 3816  104
Absence 78 74.8 (0.8) 53.0 (1.2)
Presence 22 57.6 (1.7) 36.5 (2.1)
Serum 2 microglobulin 716  104
Less than or equal to ULN 59 86.0 (1.7) 65.1 (3.9)
Greater than ULN 41 65.0 (2.8) 42.5 (3.8)
ESR 2256  104
Less than or equal to 40 mm/h 89 73.3 (1.0) 52.0 (1.4)
Greater than 40 mm/h 11 43.6 (3.2) 28.5 (3.6)
Serum LDH 2565  104
Less than or equal to ULN 79 76.6 (0.9) 53.9 (1.6)
Greater than ULN 21 57.6 (2.1) 41.4 (2.7)
Thrombocyte count 3655  104
Greater than or equal to 150 109/L 88 72.2 (0.8) 50.5 (1.2)
Less than 150 109/L 12 59.9 (2.3) 36.1 (3.1)
Hemoglobin level 3813  104
Greater than or equal to 120 g/L 82 74.9 (0.8) 51.7 (1.2)
Less than 120 g/L 18 50.7 (1.9) 35.0 (2.3)
PB lymphocyte count 3122  104
Greater than or equal to 1  109/L* 80 73.3 (0.9) 51.5 (1.3)
Less than 1  109/L 20 62.5 (2.0) 39.2 (2.6)
Serum albumin level 2116  104
Greater than or equal to 35 g/L 90 72.3 (1.0) 50.3 (1.4)
Less than 35 g/L 10 48.3 (3.5) 25.8 (4.0)
SE indicates standard error; ESR, erythrocyte sedimentation rate; LDH, lactate dehydrogenase; ULN, upper limit of normal; PB, peripheral blood; and ECOG, Eastern
Cooperative Oncology Group.
*Patients with leukemic involvement were not separated because blood involvement was considered an extra nodal site.
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candidates with 4 variable models other than age were classified according
to 2 criteria: (1) score tests, evaluated on 100 resamples of the original data
set; and (2) the Somer D coefficient adapted from Harrell et al26 for
measuring concordance of observed and expected survival, with correction
of optimism using the bootstrap technique. Risk groups were defined by
comparing the relative risk of death in patients with each possible number
of presenting risk factors (from 0 to 5). Then, categories were combined
according to the number of patients within each category, the combina-
tion producing the smallest loss of information in terms of log-
likelihood, and clinical consideration in order to obtain 3 categories of
approximately equal size.
External validation
Inclusion criteria for external validation were similar to those of the initial
study, with 2 specificities: diagnosis after January 1993, and availability of
the information on the 5 parameters of the FLIPI.
Results
Patient characteristics
Overall, 5120 patients from 27 centers or groups have been
registered (Table 1). There were 953 who were not included for
various reasons, including date of diagnosis not between 1985
and 1992 (45%), insufficient follow-up (36%), incomplete data
(8%), and other reasons (11%). There were 4167 cases included
in the final analysis. The median follow-up of surviving patients
was 7.5 years and the overall survival of these patients is shown
in Figure 2. The main clinical characteristics are shown in Table
2. Treatment modalities varied over time and according to the
institutions.
Univariate analysis
The correlations between the clinical characteristics at diagnosis
and overall survival are shown in Table 2. Given the size of the
study population, all the listed characteristics (except cell type)
were significantly associated with outcome. However, in order to
propose a simple and accurate index, the clinical and statistical
committees decided not to include all of these parameters in the
multivariate analysis. The following parameters were not included:
ESR, because this parameter was only measured in European
patients, and not in those from the United States; ECOG perfor-
mance status (PS), because the number of patients with a poor PS
(ECOG 1) was low (12%) and because there was an unexplained
difference in the percentage of patients with a poor PS between
European (14.5%) and US (2.1%) centers; serum 2 microglobulin
level and serum albumin level because of the very high proportion
of patients with missing data.
Prognostic model
Based on clinical relevance and availability of the information, 12
pretreatment characteristics were included in the multivariate
Figure 3. Numbers of patients included for designing the FLIPI. From the study
population, the remaining number of patients who had information on the 8 significant
factors after Cox analysis are mentioned. Note that no data were missing for age and
sex.
Table 3. Results of the Cox regression analysis in 1795 patients
who exhibited the 8 parameters having significant influence
on overall survival
Variable Adverse factor P RR 95% CI
Sex Male .001 1.33 1.14-1.56
Age  60 years  103 2.40 2.05-2.81
Ann Arbor stage III-IV  103 1.66 1.26-2.19
Bone marrow Involved .001 1.37 1.14-1.64
Number of nodal sites  4 .001 1.32 1.11-1.56
Hemoglobin level  120 g/L  103 1.59 1.31-1.92
PB lymphocyte count  1  109/L .008 1.27 1.06-1.52
LDH  ULN  103 1.50 1.26-1.77
RR indicates relative risk (of death); CI, confidence interval; PB, peripheral blood;
LDH, lactate dehydrogenase; and ULN, upper limit of normal.
Table 4. Results of the Cox regression analysis in 1795 patients
who exhibited the 5 parameters retained for building the Follicular
Lymphoma International Prognostic Index
Parameter Adverse factor RR 95% CI
Age  60 y 2.38 2.04-2.78
Ann Arbor stage III-IV 2.00 1.56-2.58
Hemoglobin level  120 g/L 1.55 1.30-1.88
Serum LDH level  ULN 1.50 1.27-1.77
Number of nodal sites  4 1.39 1.18-1.64
RR indicates relative risk (of death); CI, confidence interval; LDH, lactate
dehydrogenase; and ULN, upper limit of normal.
Table 5. Outcome and relative risk of death according to risk group
as defined by the Follicular Lymphoma International
Prognostic Index
Risk group
Number
of
factors*
Distribution
of
patients, %
5-year OS,
% (SE)
10-year OS,
% (SE) RR 95% CI
Low 0-1 36 90.6 (1.2) 70.7 (2.7) 1.0 NA
Intermediate 2 37 77.6 (1.6) 50.9 (2.7) 2.3 1.9-2.8
High  3 27 52.5 (2.3) 35.5 (2.8) 4.3 3.5-5.3
N  1795. OS indicates overall survival; SE, standard error; CI, confidence
interval; RR, relative risk (of death), and NA, not applicable.
*Factors adversely affecting survival in the FLIPI include age greater than 60
years; Ann Arbor stage III-IV; number of nodal sites greater than 4; serum LDH level
greater than the upper limit of normal; and hemoglobin level less than 120 g/L.
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analysis (sex, age group, Ann Arbor stage, bone marrow involve-
ment, splenic involvement, number of nodal areas involved,
number of extra nodal sites other than bone marrow, B symptoms,
anemia, lymphocytopenia, thrombocytopenia, and serum LDH
level). Both complete model and forward analyses retained 8
variables independently associated with the prognosis in a model
established on 1795 patients (Figure 3) for whom these parameters
were available (Table 3).
Prognostic index
This sample of 1795 patients comprised the population used to
build the FLIPI. Both methods retained the same 5-variable
submodel: age ( 60 years vs 60 years), Ann Arbor stage (III-IV
vs I-II), hemoglobin level ( 120 g/L vs  120 g/L), number of
nodal areas involved ( 4 vs  4), serum LDH level (above
normal vs normal or below; Table 4). In the 100 resamples of the
original data set, this 5-parameter model was classified 24 times
with the best score and 59 times as one of the 3 highest scoring
models. In terms of individual prediction, this model was also
the closest, as measured by the D coefficient,26 to the 8-param-
eter model.
Patients with a score of 5 were combined with patients with a
score of 4 because the former were too rare to constitute a category.
Patients with scores of 0 and 1 were combined because both
correspond to a group with a very good prognosis. Combining
patients with a score of 3 with those having a score of 4 or 5 yielded
the smallest log-likelihood change. The FLIPI index was thus
created with 3 risk groups: low (0-1 risk factor), intermediate (2
risk factors), high ( 3 risk factors). The distribution of patients
into these 3 groups and hazard ratios are shown in Table 5. The
survival curves are shown in Figure 4.
Comparison with the International Prognostic Index (IPI)
This comparison was performed on 1647 of 1795 patients used
for building the FLIPI for whom complete information was also
available for the parameters of the IPI (age, serum LDH level,
performance status, Ann Arbor stage, number of extra nodal
sites of disease).
The distribution of patients into the 4 IPI risk groups and the
relative risks of death are shown in Table 6. The IPI separates
the patients into 4 risk groups with significantly different
survivals. Meanwhile, the number of patients in “high” and
“high-intermediate” risk groups is low (4.7% and 15.5%,
respectively). Conversely, most of the patients are in the “low”
and “low-intermediate” risk groups (49% and 31%, respec-
tively). As shown in Figure 5, the FLIPI was discriminant as
well as in patients with low risk (P  .001), intermediate risk
(P  .001), and high-intermediate and high-risk (P  .014)
according to the IPI.
Age-adjusted model
The FLIPI was also tested in patients younger than 60 years and in
patients 60 years or older. As in the IPI study,2 the 4 risk factors
other than age were tested within each age group. The 4 other
identified risk factors (number of nodal sites, Ann Arbor stage,
serum LDH level, and hemoglobin level) remained independent
prognostic factors. Survival curves for these 2 age groups are
shown in Figure 6.
External validation
The data of 1101 other cases of patients with FL were received
from 10 groups or centers in the United States and Europe. Of
these, 92 were not analyzed because of missing values and/or
inconsistencies. Overall, 919 cases (83.5%) were included in the
analysis. The median follow-up was 6.8 years. The distribution of
the 5 parameters of the FLIPI among these 919 patients, the
distribution among the 3 FLIPI groups, and the hazard ratios are
shown in Table 7. Survival curves are shown in Figure 7.
Serum 2 microglobulin (2 M) level was measured in a greater
number of cases (65%) at the time of diagnosis for this group of
patients and thus could be studied as a factor that could potentially
add information to the FLIPI. Serum 2 M was normal in 65% of
patients and increased above the upper limit of normal in 35% of
patients. Survival curve analysis showed that there was no differ-
ence between patients with normal 2 M or increased 2 M within
each FLIPI subgroup (data not shown).
Figure 4. Survival of the 1795 patients according to risk group as defined by the
Follicular Lymphoma International Prognostic Index.
Table 6. Outcome and relative risk of death according to risk group as defined by the IPI among the 1647 patients
for whom data for the FLIPI and the IPI were available
Risk group
Number of
factors*
Distribution of
patients, %
5-year OS, %
(SE)
10-year OS, %
(SE) RR 95% CI
Low 0-1 49 88.1 (1.1) 67.3 (2.5) 1.0 NA
Low-intermediate 2 31 70.9 (2.0) 49.5 (2.8) 2.2 1.8-2.7
High-intermediate 3 15 57.4 (3.1) 27.6 (4.1) 3.5 2.8-4.3
High 4-5 5 43.6 (5.6) 35.8 (5.6) 4.5 3.3-6.2
OS indicates overall survival; SE, standard error; CI, confidence interval; RR, relative risk (of death); and NA, not applicable.
*Factors adversely affecting survival in the IPI2 include performance status greater than 1; number of extra nodal sites greater than 1; serum LDH level greater than the
upper limit of normal; Ann Arbor stage III-IV; and age greater than 60 years.
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Discussion
Among all NHLs, follicular lymphomas are the second most
frequent subtype. Unfortunately, there is no truly effective therapy
for FL, and its prognosis has remained basically unchanged over
the last 30 years.1 However, several new treatment modalities
including combination of chemotherapy and interferon alpha,27
anti-CD20 monoclonal antibodies given alone28 or bound to a radio
nuclide,29 intensive therapy with autologous stem cell transplanta-
tion,30 or nonmyeloablative allogenic stem cell transplantation31
have recently shown their activity in clinical trials. These treat-
ments have significant toxicities and are costly. To better define the
patients in whom these therapies are warranted, a prognostic index
would be very helpful.
From a large and multicentric database of patients, we were able
to propose and to validate a prognostic index for follicular
lymphomas, the FLIPI. Although inclusion criteria did not define
age limits, the median age was 56 years with 37% of patients older
than 60 years. This median age, possibly lower than that of all
patients with FL, may be related to the fact that most patients were
registered by groups and included in clinical trials (Table 1).
However, this has probably no influence on results. This index
includes parameters related to patient characteristics (age), tumor
burden (Ann Arbor stage, number of nodal sites), tumor aggressive-
ness (serum LDH level), and consequences of the lymphoma on the
host (hemoglobin level). Using this index, 3 risk groups of
approximately the same size (36%, 37%, and 27%) have been
separated. There is clearly a difference in survival between each of
these risk groups. An external validation on another group of 919
patients with FL showed a very similar distribution of patients,
highly significant differences in overall survival, and similar hazard
ratios between the 3 FLIPI subgroups. This external validation
confirms the reproducibility of the FLIPI analysis.
All the parameters of the FLIPI have been found to significantly
influence prognosis in several other analyses3-20 and have been included
Figure 5. Overall survival of patients with low IPI risk, low-intermediate IPI risk, and high-intermediate plus high IPI risk as determined by the Follicular Lymphoma
International Prognostic Index (FLIPI). (A) Low IPI risk. (B) Low-intermediate IPI risk. (C) High-intermediate and high IPI risk. Within each IPI risk group, the FLIPI can
discriminate patients in groups with significantly different death risks.
Figure 6. Survival of 1795 patients according to risk group as defined by the Follicular Lymphoma International Prognostic Index. Patients younger than 60 years (A);
patients 60 years or older (B).
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in other prognostic indices.3,4,9,12 These parameters have been routinely
evaluated in the initial staging of patients with FL for many years. This
will allow the comparison of the distribution of patients and the survival
curves of many other series’ with those reported herein and will further
evaluate the accuracy of the FLIPI. Treatment was not included in the
prognostic analysis, which concerned only initial characteristics. How-
ever, although treatments were heterogeneous, none of the treatments
given during the period of inclusion has significantly changed the
natural history of the disease.1
The number of prognostic factors used to build this index was
deliberately limited in order to obtain a simple and accurate index.
The concordance in discriminatory power between the training and
confirmation groups demonstrates the accuracy of the FLIPI. An
additional advantage of the FLIPI is that it can be used irrespective
of age group.
The FLIPI may be used for selecting treatment in individual
patients. In patients with a good prognosis (0-1 adverse factor), the
10-year overall survival is 71%. This indicates that optimal
treatment in these patients has to avoid toxicity and to preserve
quality of life. Involved-field radiation therapy for patients with
limited disease and an initial “no treatment policy,” for patients
with disseminated disease may be recommended outside clinical
trials. In contrast, patients with high-risk FL have a median survival
around 5 years. Innovative approaches such as the combination of
CVP (cyclophosphamide, vincristine, prednisone) or CHOP (CVP
plus doxorubicin) and anti-CD20 monoclonal antibody,32 purine
analog-based regimens,33 and autologous stem cell transplanta-
tion30 followed by vaccine therapies34 may be studied in this
subgroup. All these approaches have been so far evaluated in phase
2 studies. The size of the high-risk group (27% of patients in the
sample used for creating this index and 28% in the sample used for
validation) could allow the design of multicenter randomized trials.
In conclusion, the FLIPI is an extremely simple and reproduc-
ible prognostic index, based on easily available clinical data, for
patients with FL. This index may be a useful tool for improving the
prognostic assessment of patients with FL. It can also be of help in
selecting the most appropriate treatment in individual patients and
in stratifying patients in prospective trials.
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